The American Heart Association (AHA) is one of many entities concerned about the wellbeing of schoolchildren after the U.S. Department of Agriculture (USDA) eased up on its nutrition standards for school lunches late last year.

NEW YORK, Jan. 22, 2018 — Noted cardiologists, Jennifer H. Mieres, MD, and Stacey E. Rosen, MD, launch Heart Smart For Women; Six S.T.E.P.S. in Six Weeks To Heart- Healthy Living; a new book that demystifies the science, biology and statistics surrounding heart disease while providing a user-friendly program for successful heart-healthy living.

Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

Women who present at a hospital with non-ST segment elevated MI (non-STEMI) are more likely to die than men, but they are also six years older on average and have a higher burden of comorbidities, researchers reported in Circulation: Cardiovascular Interventions.

Bikram yoga—a form of “hot yoga” in which poses are practiced in a room heated to upwards of 104 degrees Fahrenheit (40 degrees Celsius)—has cardiovascular benefits, but no more than yoga practiced at room-temperature, teams at the University of Texas at Austin and Texas State University have found.

When third-grader Ava Rao was diagnosed with type 1 diabetes, it changed life for her whole family. Now a high school freshman, Ava and her dad, cardiologist Sunil V. Rao, MD, share their perspectives on the disease and hopes for the future. 

Nearly half of all out-of-hospital cardiac arrest (OHCA) survivors struggle to rejoin the workforce and participate in society post-heart attack, a study published in Circulation: Cardiovascular Quality and Outcomes suggests.

TITUSVILLE, N.J., Jan. 16, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced findings from the U.S. Food and Drug Administration's (FDA) Mini-Sentinel assessment, confirming the positive safety and efficacy profile of XARELTO® (rivaroxaban) established in the phase III ROCKET AF clinical trials, were published in Pharmacoepidemiology & Drug Safety.